Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia

Leukemia Research

Volumn 31, Issue 10, 2007, Pages 1383-1388

  Qian, Si Xuan ^a   Li, Jian Yong ^a   Tian, Tian ^a   Shen, Yun Feng ^a   Jiang, Yuan Qiang ^a   Lu, Hua ^a   Wu, Han Xin ^a   Zhang, Su Jiang ^a   Xu, Wei ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Aclarubicin; Acute myeloid leukaemia; Cytarabine; Granulocyte colony stimutating factor (G CSF); Priming

Indexed keywords

ACLARUBICIN; ANTHRACYCLINE DERIVATIVE; CYTARABINE; DAUNORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAL INFECTION; ANUS DISEASE; APPENDICITIS; ARTICLE; BILIARY TRACT INFECTION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CHINESE; CHROMOSOME ABERRATION; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOW DRUG DOSE; LUNG INFECTION; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SEPTICEMIA; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; URINARY TRACT INFECTION;

ACLARUBICIN; ACUTE DISEASE; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 34547702377     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.02.009     Document Type: Article

References (21)

1. Lowenberg B., van Putten W., Theobald M., Gmur J., Verdonck L., Sonneveld P., et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 349 (2003) 743-752
2. Grimwade D., Walker H., Oliver F., Wheatley K., Harrison C., Harrison G., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 Trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92 (1998) 2322-2333
3. Tallman M.S. New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents. Hematology (Am Soc Hematol Educ Program) (2005) 143-150
4. Saito K., Nakamura Y., Aoyagi M., Waga K., Yamamoto K., Aoyagi A., et al. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation. Int J Hematol 71 (2000) 238-244
5. Cheson B.D., Bennett J.M., Kopecky K.J., Buchner T., Willman C.L., Estey E.H., et al. Reviewed recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21 (2003) 4642-4649
6. Slovak M.L., Kopecky K.J., Cassileth P.A., Harrington D.H., Theil K.S., Mohamed A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96 (2000) 4075-4083
7. Kaplan E., and Meier P. Nonparametric estimation from incomplete observation. J Am Statist Assoc 53 (1958) 457-481
8. Hoyle C.F., de Bastos M., Wheatley K., Sherrington P.D., Fischer P.J., Rees J.K., et al. AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial. Br J Haematol 72 (1989) 45-53
9. Hofmann W.K., Heil G., Zander C., Wiebe S., Ottmann O.G., Bergmann L., et al. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Ann Hematol 83 (2004) 498-503
10. Latagliata R., Bongarzoni V., Carmosino I., Mengarelli A., Breccia M., Borza P.A., et al. Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon. Ann Oncol 17 (2006) 281-285
11. Kantarjian H., O'brien S., Cortes J., Giles F., Faderl S., Jabbour E., et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 106 (2006) 1090-1098
12. Amadori S., et al. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood 106 (2005) 27-34
13. Löfgren C., Paul C., Astrom M., et al. Granulocyte-macrophage colony-stimulating factor to increase efficacy of mitoxantrone, etoposide and cytarabine in previously untreated elderly patients with acute myeloid leukaemia: a Swedish multicentre randomized trial. Br J Haematol 124 (2004) 474-480
14. Estey E., Thall P.F., Kantarjian H., et al. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C+ daunorubicin: comparison to patients treated without GM-CSF. Blood 79 (1992) 2246-2255
15. Witz F., Sadoun A., Perrin M.C., et al. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients: Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 91 (1998) 2722-2730
16. Nimubona S., Grulois I., Bernard M., Drenou B., Godard M., Fauchet R., et al. Complete remission in hypoplastic acute myeloid leukemia induced by G-CSF without chemotherapy: report on three cases. Leukemia 16 (2002) 1872-1873
17. Fujiwara H., Arma N., Matsushita K., Hidaka S., Ohtsubo H., Fukumori J., et al. Granulocyte-conoly stimulating factor induces differentiation and apoptosis of CD2, CD7 positive hybrid leukemia cells in vivo and ex vivo. Leuk Res 21 (1997) 735-741
18. Takahashi M., Koike T., Aizawa Y., Kashimura M., Hayatsu K., Nagai K., et al. Complete remission in three patients with acute myeloblastic leukemia by administration of G-CSF without antileukemic agents. Am J Hematol 56 (1997) 42-44
19. Byrd J.C., Mrozek K., Dodge R.K., Carroll A.J., Edwards C.G., Arthur D.C., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100 (2002) 4325-4336
20. Lang K., Earle C.C., Foster T., Dixon D., Van Gool R., and Menzin J. Trends in the treatment of acute myeloid leukemia in the elderly. Drug Aging 22 (2005) 943-955
21. Menzin J., Lang K., Earle C.C., Kerney D., and Mallick R. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med 162 (2002) 1597-1603